Compare BL & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BL | AVLN |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | 1850 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 2016 | 2026 |
| Metric | BL | AVLN |
|---|---|---|
| Price | $30.26 | $39.31 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $56.62 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 190.5K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $177,031,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $10.90 | N/A |
| P/E Ratio | $78.40 | ★ N/A |
| Revenue Growth | ★ 43.78 | N/A |
| 52 Week Low | $24.70 | $24.90 |
| 52 Week High | $59.57 | $39.99 |
| Indicator | BL | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 73.88 |
| Support Level | $29.23 | $26.38 |
| Resistance Level | $31.14 | N/A |
| Average True Range (ATR) | 1.57 | 2.24 |
| MACD | -0.15 | 1.04 |
| Stochastic Oscillator | 46.70 | 92.56 |
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.